Skip to main content
Evidence Snapshot

Trace amine-associated receptor 1

CHEMBL5857 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:56:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5857
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Trace amine-associated receptor 1 as ChEMBL target CHEMBL5857, mapped to UniProt Q96RJ0. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Trace amine-associated receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5857
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q96RJ0
Trace amine-associated receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Trace amine-associated receptor 1 matters

As of 2026-09-13

Trace amine-associated receptor 1 is reviewed as Trace amine-associated receptor 1 (UniProt Q96RJ0); Trace amine-associated receptor 1 shows late clinical disease relevance led by schizophrenia. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 18 approved drugs, 779 compounds, and 50 assays, with lead potency reaching pChEMBL 8.9.

Disease context
schizophrenia

Trace amine-associated receptor 1 shows late clinical disease relevance led by schizophrenia. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include ULOTARONT.

Start review with schizophrenia because it currently carries late clinical support. Linked drugs include ULOTARONT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 18 approved drugs, 779 compounds, and 50 assays for this target. The dominant activity type is EC50. CHEMBL4301324 is the current potency anchor at pChEMBL 8.9.

Use CHEMBL4301324 as the tractability anchor when discussing potency (pChEMBL 8.9).

Activity source · ChEMBL 36 via Core Engine
18 approved pChEMBL 8.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Trace amine-associated receptor 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q96RJ0, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why schizophrenia is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

779
Total Compounds
50
Total Assays
18
Approved Drugs
IC50: 458.0, KI: 50.0, EC50: 781.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4301324
 8.9 EC50 —
No preferred name
CHEMBL2206400
 8.7 Ki —
No preferred name
CHEMBL2206385
 8.7 Ki —
No preferred name
CHEMBL5082760
 8.5 EC50 —
No preferred name
CHEMBL2206890
 8.4 Ki —

Approved Drugs

Structure Compound First Approval
TOLAZOLINE HYDROCHLORIDE
CHEMBL1689
 1985
GUANABENZ
CHEMBL420
 1982
TETRAHYDROZOLINE HYDROCHLORIDE
CHEMBL1200413
 1979
NAPHAZOLINE HYDROCHLORIDE
CHEMBL1706
 1971
DEXTROAMPHETAMINE
CHEMBL612
 1955
LEVAMFETAMINE
CHEMBL19393
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:56:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5857